Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Mar-Apr;28(2):554-63.
doi: 10.1111/jvim.12313. Epub 2014 Feb 10.

Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma

L E Selmic  1 , J H Burton, D H Thamm, S J Withrow, S E Lana
Affiliations
Comparative Study

Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma

L E Selmic et al. J Vet Intern Med. 2014 Mar-Apr.

Abstract

Background: Many chemotherapy protocols have been reported for treatment of canine appendicular osteosarcoma (OSA), but outcome comparisons in a single population are lacking.

Objective: To evaluate the effects of protocol and dose intensity (DI) on treatment outcomes for carboplatin and doxorubicin-based chemotherapy protocols.

Animals: Four hundred and seventy dogs with appendicular OSA.

Methods: A retrospective cohort study was performed comprising consecutive dogs treated (1997-2012) with amputation followed by 1 of 5 chemotherapy protocols: carboplatin 300 mg/m(2) IV q21d for 4 or 6 cycles (CARBO6), doxorubicin 30 mg/m(2) IV q14d or q21d for 5 cycles, and alternating carboplatin 300 mg/m(2) IV and doxorubicin 30 mg/m(2) IV q21d for 3 cycles. Adverse events (AE) and DI were evaluated. Kaplan-Meier survival curves and Cox proportional hazards regression were used to compare disease-free interval (DFI) and survival time (ST) among protocols.

Results: The overall median DFI and ST were 291 days and 284 days, respectively. A lower proportion of dogs prescribed CARBO6 experienced AEs compared to other protocols (48.4% versus 60.8-75.8%; P = .001). DI was not associated with development of metastases or death. After adjustment for baseline characteristics and prognostic factors, none of the protocols provided a significant reduction in risk of development of metastases or death.

Conclusions and clinical importance: Although choice of protocol did not result in significant differences in DFI or ST, the CARBO6 protocol resulted in a lower proportion of dogs experiencing AEs, which could be advantageous in maintaining high quality of life during treatment. DI was not a prognostic indicator in this study.

Keywords: Canine; Limb amputation; Oncology; Primary bone tumor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Temporal distribution of the prescribed chemotherapy protocols over the study period.
Figure 2
Figure 2
Distribution of type of adverse events by chemotherapy protocol.
See this image and copyright information in PMC

References

    1. Straw RC, Withrow SJ, Powers BE. Management of canine appendicular osteosarcoma. Vet Clin North Am Small Animal Pract 1990;20:1141–1161. - PubMed
    1. Ehrhart NP, Ryan SD, Fan TM. Tumors of the skeletal system In: Withrow SJ, Vail DM, Page RL, eds. Withrow & MacEwen's Small Animal Clinical Oncology, 5th ed St. Louis, MO: Elsevier; 2013:463–503.
    1. Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb‐sparing surgery: 22 cases (1987‐1990). J Am Vet Med Assoc 1992;200:2005–2008. - PubMed
    1. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343–1350. - PubMed
    1. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991;5:205–210. - PubMed

Publication types

MeSH terms